Details for New Drug Application (NDA): 209953
✉ Email this page to a colleague
The generic ingredient in RANOLAZINE is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
Summary for 209953
Tradename: | RANOLAZINE |
Applicant: | Alkem Labs Ltd |
Ingredient: | ranolazine |
Patents: | 0 |
Suppliers and Packaging for NDA: 209953
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 209953 | ANDA | AvPAK | 50268-722 | 50268-722-15 | 50 BLISTER PACK in 1 BOX (50268-722-15) / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (50268-722-11) |
RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 209953 | ANDA | AvPAK | 50268-723 | 50268-723-13 | 30 BLISTER PACK in 1 BOX (50268-723-13) / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (50268-723-11) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG | ||||
Approval Date: | Nov 30, 2020 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM | ||||
Approval Date: | Nov 30, 2020 | TE: | AB | RLD: | No |
Complete Access Available with Subscription